RenalSense™ is a medical device company dedicated to real-time renal diagnostics.

 

The founders of RenalSense have long recognized the need for a more sensitive method of monitoring renal function in critically ill patients, in order to detect the risk of Acute Kidney Injury (AKI) and enable early intervention. We realized that current approaches such as manual and intermittent measurements of urine output, or daily blood tests of kidney function indicators, are unreliable, or too late.

 

Since 2009, our team of critical care and nephrology specialists has been working closely with our technology experts to develop a reliable, practical, and viable solution to this problem.

 

Our answer is Clarity RMS™ – an elegant solution that continuously and automatically monitors urine flow for real-time assessment of changes in renal function and detection of AKI risk.

 

While we continue our ongoing clinical trials and product development, we look forward to launching our product and setting a new gold standard for management of critical care patients. This will facilitate early therapeutic intervention, as well as improved fluid management, for patients at risk of AKI.

 

Not only will this be game-changing for ICU patient care, we believe it will also significantly improve ICU economics by reducing the need for extended ICU stays due to AKI, dramatically lowering costs, and increasing patient turnover.

Products

Events

Events not available

News

ICU Management

COVID-19 and Acute Kidney Injury

2020 03 Jun

Incidence and risk factors for acute kidney injury (AKI) in COVID-19 patients Recent reports from China, Italy, and the US indicate that there is a 25-37% incidence of AKI among critically ill COVID-19 patients (Singh 2020, Hirsch et al. 2020). In a study of 5449 hospitalized COVID-19 patients, AKI was observed primarily in patients with respiratory... Read more

ICU Management

RenalSense starts delivery of its first orders of Clarity RMS in Europe

2020 23 Apr

RenalSense has started commercial sales of its Clarity RMSTM system in Europe in conjunction with its distribution partner Fresenius Medical Care (Bad Homburg). The Clarity RMS received CE Mark approval in August 2019. AKI occurs in over 55% of ICU patients, and is often associated with a high risk of chronic kidney disease, as well as increased... Read more

Jobs not available

Catalogue

    Catalogue not available

Hamarpe, 3
Jerusalem
9145101
+972 2 502 2562

White Papers - Case Studies

ICU Management

Oliguria And The Role Of Urine Monitoring In Renal Replacement Therapy (RRT) Management

2020 28 Jul

ABSTRACT Renal Replacement Therapy (RRT) is a complex treatment modality for a high-risk, critical care patient population with advanced AKI. While there are still no clear guidelines regarding the timing of initiation and termination of RRT, there is a growing body of evidence supporting the importance of urine monitoring and the clinical significance... Read more

ICU Management

The Importance Of Continuous Monitoring Of Urine Flow In Critical Care Patients

2020 30 Jun

ABSTRACT This review discusses the importance of continuous, real-time monitoring of urine flow in critical care patients and its potential role in Acute Kidney Injury (AKI) and fluid management in a variety of clinical conditions.  Real-time, reliable monitoring of urine flow enables clinicians to detect early signs of kidney injury, and facilitates... Read more

Videos

Articles

Not available